Riboflavin (Vitamin B2) for Migraine Prevention

Table of Contents

1. Migraine and Brain Energy Metabolism
2. Where Riboflavin Sits in Energy Production
3. The Schoenen 1998 Neurology Trial
4. Doses and Absorption
5. How Long the Studies Lasted
6. Guidelines and Reviews (AAN/AHS 2012, Retired 2015)
7. Pediatric Migraine Evidence (Condò, MacLennan, Bruijn)
8. Riboflavin, CoQ10 and Magnesium: the Related Trials
9. Bright Yellow Urine
10. Reported Side Effects
11. Doses Used in the Studies
12. Common Questions
13. Cautions
14. Key Research Papers
15. Connections
16. Featured Videos

Migraine and Brain Energy Metabolism

Migraine was long framed as a vascular disorder, with the throbbing pain blamed on dilated cranial arteries. Current models center on the brain itself, including cortical spreading depression — a slow wave of neuronal and glial depolarization that moves across the cortex and is linked to the aura and to activation of the pain pathways.

One line of research proposes that the migraine brain works with a smaller energy reserve. The main evidence comes from small phosphorus-31 magnetic resonance spectroscopy (³¹P-MRS) studies:

• Welch et al. 1988 (Cephalalgia) measured the intracellular pH of the cerebral cortex and found no change during a migraine attack; the authors wrote that the old idea of headache caused by vasospasm-induced ischemic acidosis was not substantiated.
• Welch et al. 1989 (Neurology) found that during attacks ATP was preserved but phosphocreatine fell and inorganic phosphate rose, lowering the phosphocreatine/phosphate ratio (an index of phosphorylation potential). This was found in migraine with aura (classic) but not in migraine without aura (common). Inorganic phosphate was also raised between attacks, and brain pH did not change.
• Barbiroli et al. 1992 (Neurology) studied 12 patients with migraine with aura between attacks: all had low brain phosphocreatine, with high ADP and low phosphorylation potential, and nine of the 12 had abnormal muscle mitochondrial function without muscle symptoms.
• Ramadan et al. 1989 (Headache) found low brain magnesium during migraine attacks, without changes in pH.
• Di Lorenzo et al. 2009 (Neurology) gave 64 people with migraine riboflavin 400 mg once daily in a 4-month open trial: 40 responded and 24 did not. Responders were more often outside mitochondrial DNA haplogroup H (67.5%), and non-responders were mostly haplogroup H (66.7%; p = 0.01). The authors note the mechanism is unknown.

Schoenen's group built the riboflavin trial on this idea; its abstract opens: "A deficit of mitochondrial energy metabolism may play a role in migraine pathogenesis." The energy-reserve model remains a hypothesis, and the imaging studies behind it are small.

Back to Table of Contents

Where Riboflavin Sits in Energy Production

Riboflavin is the precursor of two flavin coenzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), which sit at several points in the mitochondrial energy machinery:

• FMN in Complex I (NADH:ubiquinone oxidoreductase) — accepts electrons from NADH and passes them along the complex's iron-sulfur clusters.
• FAD in Complex II (succinate dehydrogenase) — covalently bound to the SDHA subunit; succinate dehydrogenase belongs to both the Krebs cycle and the electron transport chain.
• FAD in electron-transferring flavoprotein (ETF), ETF-ubiquinone oxidoreductase and the acyl-CoA dehydrogenases — the route that feeds electrons from fatty-acid oxidation into the respiratory chain.
• FMN in pyridoxine-5′-phosphate oxidase — the enzyme that converts vitamin B6 to its coenzyme form, pyridoxal 5′-phosphate.

The proposed link to migraine is that high-dose riboflavin raises the supply of these coenzymes and so improves mitochondrial energy output in the brain. That is a hypothesis: the clinical studies on this page measured headaches, not brain energy, and none of them shows how riboflavin acts in migraine.

Back to Table of Contents

The Schoenen 1998 Neurology Trial

Schoenen, Jacquy and Lenaerts (Neurology 1998;50(2):466-470) followed an earlier open study by randomizing 55 patients with migraine to riboflavin 400 mg or placebo for 3 months. As reported in the abstract, using an intention-to-treat analysis:

• Riboflavin was superior to placebo in reducing attack frequency (p = 0.005) and headache days (p = 0.012).
• For headache days, 59% of the riboflavin group and 15% of the placebo group improved by at least 50% ("responders"; p = 0.002). The number needed to treat was 2.3.
• Three minor adverse events occurred: diarrhea and polyuria in the riboflavin group and abdominal cramps in the placebo group. None was serious.
• The authors called riboflavin "a candidate for a comparative trial with an established prophylactic drug"; the trial itself did not compare riboflavin with any drug.

The abstract does not report the average number of attacks a month in each group.

Responder results as reported in each trial abstract. Schoenen 1998 counted headache days; MacLennan 2008 counted migraine attacks per 4 weeks; Maizels 2004 counted migraines and compared the combination with a 25 mg riboflavin "placebo".

Other studies of riboflavin alone:

• Boehnke et al. 2004 (European Journal of Neurology) — an open-label study in a specialist clinic, with no placebo group. With riboflavin 400 mg a day, headache frequency fell from 4 days a month at baseline to 2 days a month after 3 and 6 months (P < 0.05), and use of acute migraine drugs fell from 7 to 4.5 units a month. Headache hours and intensity did not change significantly.
• Di Lorenzo et al. 2009 — the 4-month open trial of 400 mg described above, in which 40 of 64 patients responded.
• The pediatric trials (MacLennan 2008, Bruijn 2010) and the pediatric case series (Condò 2009) are covered in the pediatric section below.

Back to Table of Contents

Doses and Absorption

The doses studied for migraine are far above the amounts in the Recommended Dietary Allowance, and the gut can absorb only part of a large single dose:

• Absorption has a ceiling. In a pharmacokinetic study of nine healthy adults given single oral doses of 20, 40 and 60 mg (Zempleni et al. 1996, American Journal of Clinical Nutrition), the maximal amount of riboflavin that could be absorbed from a single dose was 27 mg. Urinary excretion accounted for about one-half of riboflavin's removal from the blood.
• No trial cited here compared 400 mg with lower doses in the same group of patients.
• Lower-dose trials in children were negative — 200 mg a day (MacLennan 2008) and 50 mg a day (Bruijn 2010) did not reduce migraine attacks more than placebo. Because these trials studied children, dose and age cannot be separated.
• A 25 mg control group did about as well as 400 mg. In Maizels et al. 2004, adults given riboflavin 25 mg as the "placebo" improved as often as those given a combination containing 400 mg (44% vs 42% with at least a 50% reduction in migraines); the authors suggested 25 mg may itself be an active comparator.
• The pooled analysis by Chen et al. (2022) concluded that riboflavin 400 mg a day for three months had a significant effect on migraine days, duration, frequency and pain score.

Back to Table of Contents

How Long the Studies Lasted

Riboflavin has been studied only as a preventive taken daily, not as a treatment for an attack already under way. The studies cited here ran for these periods:

• Schoenen 1998: 3 months of treatment.
• Boehnke 2004: outcomes recorded at baseline and after 3 and 6 months.
• Di Lorenzo 2009: a 4-month open trial.
• Condò 2009 (children): 3, 4 or 6 months.
• Bruijn 2010 (children): 16 weeks on riboflavin and 16 weeks on placebo.
• Chen 2022 meta-analysis: its conclusion refers to 400 mg a day for three months.

The abstracts cited here do not report a week-by-week time course of the effect, and none reports what happens after riboflavin is stopped.

Back to Table of Contents

Guidelines and Reviews (AAN/AHS 2012, Retired 2015)

The 2012 AAN / AHS guideline — retired in 2015

The 2012 evidence-based guideline of the American Academy of Neurology and the American Headache Society on NSAIDs and complementary treatments for episodic migraine prevention in adults (Holland et al., Neurology) reviewed studies published from June 1999 to May 2009 and graded:

• Level A (effective): butterbur (Petasites)
• Level B (probably effective): fenoprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium, a feverfew extract, magnesium, riboflavin and subcutaneous histamine
• Level C (possibly effective): cyproheptadine, CoQ10, estrogen, mefenamic acid and flurbiprofen
• Conflicting or inadequate data: aspirin, indomethacin, omega-3 and hyperbaric oxygen

The guideline has been retired. According to the retirement notice now printed with it, the AAN Board of Directors retired the guideline on September 16, 2015, "due to serious safety concerns with a preventative treatment, butterbur, recommended by this guideline." The notice states that the recommendations and conclusions of retired guidelines are considered no longer valid and no longer supported by the AAN, and remain available for reference only. The Level B grade for riboflavin is therefore a historical grading, not a current AAN position.

The 2012 Canadian Headache Society guideline

The Canadian Headache Society guideline for migraine prophylaxis (Pringsheim et al., Canadian Journal of Neurological Sciences 2012), which covers episodic migraine, graded its recommendations with the GRADE system. It gave a strong recommendation to 11 prophylactic treatments — topiramate, propranolol, nadolol, metoprolol, amitriptyline, gabapentin, candesartan, butterbur, riboflavin, coenzyme Q10 and magnesium citrate — and a weak recommendation to six others. Its abstract states that the quality of evidence varied from high to low between medications and that the choice for an individual patient "requires careful consideration of patient clinical features."

What the reviews conclude

• Namazi et al. 2015 (International Journal for Vitamin and Nutrition Research) — a review of 11 articles (seven in adults, four in children). Riboflavin in adults played a positive role in reducing the frequency and duration of attacks with no serious side effects, but the authors found "insufficient evidence to make recommendations regarding vitamin B2 as an adjunct therapy in adults and children."
• Thompson and Saluja 2017 (Journal of Clinical Pharmacy and Therapeutics) — a systematic review of 11 clinical trials: five in adults showed a consistent positive effect, four in children and adolescents showed a mixed effect, and two of combination products did not show benefit. Adverse reactions were generally mild. The authors call for more data on pharmacokinetic and pharmacogenomic questions.
• Chen et al. 2022 (Nutritional Neuroscience) — a meta-analysis of nine studies (eight randomized trials and one controlled clinical trial; 673 participants). Riboflavin significantly reduced migraine days (p = .005), duration (p = .003), frequency (p = .001) and pain score (p = .015). Heterogeneity between studies was high for migraine days (I² = 89%) and pain score (I² = 84%).
• Talandashti et al. 2025 (Neurological Sciences) — a dose-response meta-analysis of 22 trials of several supplements; riboflavin decreased attack frequency (mean difference −1.34).

Back to Table of Contents

Pediatric Migraine Evidence (Condò, MacLennan, Bruijn)

The placebo-controlled trials in children did not find a benefit on migraine attacks; the one uncontrolled series did report improvement.

• MacLennan et al. 2008 (Journal of Child Neurology) — the first randomized, double-blind trial in children: riboflavin 200 mg daily or placebo in 48 children. A 50% or greater reduction in attacks per 4 weeks occurred in 12 of 27 children on riboflavin and 14 of 21 on placebo (P = .125, not significant), and there were no differences in any secondary outcome. The authors concluded the results "suggest that riboflavin is not an effective therapy for preventing migraine in children" and noted a high placebo response.
• Bruijn et al. 2010 (Cephalalgia) — a randomized, double-blind crossover trial in 42 children aged 6-13, 14 of whom also had tension-type headache, comparing riboflavin 50 mg a day with placebo for 16 weeks each. There was no significant difference in migraine attack frequency (P = 0.44). Headaches with a tension-type pattern fell more with riboflavin (P = 0.04).
• Condò et al. 2009 (Journal of Headache and Pain) — a retrospective report, without a control group, on 41 children and adolescents given 200 or 400 mg once daily for 3, 4 or 6 months. Attack frequency and intensity decreased (P < 0.01), and during follow-up 68.4% had a 50% or greater reduction in attack frequency. Two patients had vomiting and increased appetite, which the authors judged most likely unrelated to riboflavin.
• Kohandel Gargari et al. 2024 (JAMA Network Open) — a network meta-analysis of 45 pediatric prevention trials (3,771 participants). Riboflavin was associated with fewer attacks than placebo (ratio of means 0.50; 95% CI 0.32-0.77), but the authors note this finding was drawn from individual studies and that more studies are required for a robust conclusion.

Back to Table of Contents

Riboflavin, CoQ10 and Magnesium: the Related Trials

Riboflavin, coenzyme Q10 and magnesium are often discussed together as a "mitochondrial" group of migraine supplements. Each has its own small trials:

• Coenzyme Q10 — carries electrons from Complexes I and II to Complex III. In a randomized trial in 42 patients (Sandor et al. 2005), 100 mg three times a day was superior to placebo in the third month; the 50% responder rate for attack frequency was 47.6% with CoQ10 and 14.4% with placebo (number needed to treat 3). In an uncontrolled clinic series of children and adolescents (Hershey et al. 2007), 32.9% of 1,550 patients tested had CoQ10 levels below the reference range; in those who returned for follow-up after supplementation, headache frequency fell from 19.2 to 12.5 (P < .001), and the authors call for more rigorous studies to confirm this.
• Magnesium — graded Level B in the retired 2012 AAN/AHS guideline; magnesium citrate received a strong recommendation in the 2012 Canadian guideline.

The combination trials

• Maizels et al. 2004 (Headache) — a combination of riboflavin 400 mg, magnesium 300 mg and feverfew 100 mg a day against a "placebo" containing riboflavin 25 mg for 3 months. Of 49 patients who completed the trial, 10 (42%) on the combination and 11 (44%) on the control had a 50% or greater reduction in migraines (P = .87). Both groups improved significantly from baseline.
• Gaul et al. 2015 (Journal of Headache and Pain) — 130 adults with at least three attacks a month received a proprietary fixed combination of magnesium, riboflavin and CoQ10, or placebo, for 3 months. Migraine days a month fell from 6.2 to 4.4 with the supplement and from 6.2 to 5.2 with placebo, a difference that was not significant (p = 0.23). Pain intensity (p = 0.03) and the HIT-6 burden-of-disease score (down 4.8 points, from 61.9 to 57.1, vs 2 points with placebo; p = 0.01) improved more with the supplement.

A related mitochondrial agent, thioctic (alpha-lipoic) acid, was tested by Magis et al. 2007 (Headache): 44 patients received 600 mg a day or placebo for 3 months. The 50% responder rate did not differ (30.8% vs 27.8%), attack frequency tended to fall more with thioctic acid (P = .06), and the trial stopped early, before the planned 80 patients were enrolled.

No trial cited on this page tests whether combining riboflavin, CoQ10 and magnesium works better than any one of them alone.

Back to Table of Contents

Bright Yellow Urine

High doses of riboflavin turn urine bright yellow. Riboflavin itself is a yellow compound, and the kidneys clear much of what is absorbed: in the Zempleni 1996 pharmacokinetic study, urinary excretion accounted for about one-half of riboflavin's removal from the blood. The color is harmless and is not one of the adverse events counted in the trials.

The studies cited on this page do not test urine color as a measure of how much riboflavin is absorbed, of adherence, or of benefit.

Back to Table of Contents

Reported Side Effects

The studies cited here report few adverse effects:

• Schoenen 1998: three minor adverse events — diarrhea and polyuria with riboflavin, abdominal cramps with placebo; none serious.
• Boehnke 2004: the authors describe riboflavin as safe and well tolerated.
• Condò 2009: vomiting in one patient and increased appetite in another, judged most likely unrelated.
• Namazi 2015 and Thompson 2017 (reviews): no serious side effects; adverse reactions generally mild.

The trials were small and short, so rare or long-term effects would not be detected. None of the riboflavin studies cited here compared its side effects directly with those of a prescription migraine preventive.

Back to Table of Contents

Doses Used in the Studies

These are the regimens the studies reported, not dosing instructions:

• Adults, riboflavin alone: 400 mg a day for 3 months (Schoenen 1998); 400 mg a day, assessed at 3 and 6 months (Boehnke 2004); 400 mg once daily for 4 months (Di Lorenzo 2009).
• Children: 200 mg a day (MacLennan 2008); 50 mg a day (Bruijn 2010); 200 or 400 mg once daily (Condò 2009).
• Combinations: riboflavin 400 mg + magnesium 300 mg + feverfew 100 mg a day (Maizels 2004); a fixed combination of magnesium, riboflavin and CoQ10 (Gaul 2015).
• Related agents: CoQ10 100 mg three times a day (Sandor 2005); thioctic acid 600 mg a day (Magis 2007).

Decisions about supplements, and about combining them with migraine medicines, belong with a clinician.

Back to Table of Contents

Common Questions

Q: Does riboflavin stop a migraine attack in progress?
It has been studied only as a daily preventive; the studies cited here did not test it as a treatment for an attack under way.

Q: How long did the trials run?
Most ran 3 to 6 months; the Schoenen trial's results were measured after 3 months. The abstracts do not report a week-by-week time course.

Q: Is the bright yellow urine harmful?
It reflects riboflavin cleared by the kidneys and is not counted as an adverse event in the trials.

Q: What about combining it with migraine medicines?
None of the studies cited here was designed to test interactions between high-dose riboflavin and migraine medicines, and their abstracts report none. Decisions about combining treatments belong with a clinician.

Q: What about children?
Two placebo-controlled trials in children (200 mg and 50 mg a day) did not find a benefit on migraine attacks; an uncontrolled case series at 200-400 mg reported improvement. A 2024 network meta-analysis found an association with fewer attacks but called for more studies.

Q: What about pregnancy?
Riboflavin is needed in pregnancy, but none of the studies cited here tested high doses such as 400 mg a day in pregnant women.

Q: Is long-term use studied?
The longest studies cited here lasted about 6 months. Longer-term data at these doses are not reported in them.

Back to Table of Contents

Cautions

• Small evidence base — the placebo-controlled trials enrolled 42 to 130 people each, and the reviews describe mixed results in children and in combination products.
• Children — the placebo-controlled pediatric trials at 200 mg and 50 mg a day did not find a benefit on migraine attacks.
• Pregnancy — high doses have not been tested in the studies cited here.
• Not an acute treatment — riboflavin was studied only as a daily preventive.
• Light sensitivity — riboflavin is broken down by light.
• Guideline status — the AAN/AHS guideline often quoted for riboflavin's Level B grade was retired in 2015; the Canadian Headache Society's 2012 guideline gave it a strong recommendation.

Back to Table of Contents

Key Research Papers

1. Schoenen J, Jacquy J, Lenaerts M (1998). Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 50(2):466-470. — PubMed PMID: 9484373
2. Boehnke C et al. (2004). High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. European Journal of Neurology. — PubMed PMID: 15257686
3. Holland S et al. (2012). Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology 78(17):1346-1353 (AAN/AHS guideline). Retired by the AAN on September 16, 2015 (retirement notice printed with the PMC copy, PMC3335449). — PubMed PMID: 22529203
4. Condò M et al. (2009). Riboflavin prophylaxis in pediatric and adolescent migraine. Journal of Headache and Pain. — PubMed PMID: 19649688
5. MacLennan SC et al. (2008). High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. Journal of Child Neurology. — PubMed PMID: 18984840
6. Bruijn J et al. (2010). Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia. — PubMed PMID: 20974610
7. Maizels M et al. (2004). A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. — PubMed PMID: 15447697
8. Sandor PS et al. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. — PubMed PMID: 15728298
9. Hershey AD et al. (2007). Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 47(1):73-80. — PubMed PMID: 17355497
10. Namazi N et al. (2015). Supplementation with riboflavin (vitamin B2) for migraine prophylaxis in adults and children: a review. International Journal for Vitamin and Nutrition Research 85(1-2):79-87. — PubMed PMID: 26780280
11. Magis D et al. (2007). A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache. — PubMed PMID: 17355494
12. Welch KM, Levine SR, D'Andrea G, Helpern JA (1988). Brain pH in migraine: an in vivo phosphorus-31 magnetic resonance spectroscopy study. Cephalalgia 8(4):273-277. — PubMed PMID: 3219729
13. Barbiroli B et al. (1992). Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 42(6):1209-1214. — PubMed PMID: 1603349
14. Pringsheim T, Davenport W, Mackie G, et al. (2012). Canadian Headache Society guideline for migraine prophylaxis. Canadian Journal of Neurological Sciences 39(2 Suppl 2):S1-59. — PubMed PMID: 22683887
15. Thompson DF, Saluja HS (2017). Prophylaxis of migraine headaches with riboflavin: a systematic review. Journal of Clinical Pharmacy and Therapeutics 42(4):394-403. — PubMed PMID: 28485121
16. Chen YS, Lee HF, Tsai CH, et al. (2022). Effect of vitamin B2 supplementation on migraine prophylaxis: a systematic review and meta-analysis. Nutritional Neuroscience 25(9):1801-1812. — PubMed PMID: 33779525
17. Kohandel Gargari O, Aghajanian S, Togha M, et al. (2024). Preventive medications in pediatric migraine: a network meta-analysis. JAMA Network Open 7(10):e2438666. — PubMed PMID: 39388181
18. Talandashti MK, Shahinfar H, Delgarm P, Jazayeri S (2025). Effects of selected dietary supplements on migraine prophylaxis: a systematic review and dose-response meta-analysis of randomized controlled trials. Neurological Sciences 46(2):651-670. — PubMed PMID: 39404918
19. Di Lorenzo C, Pierelli F, Coppola G, et al. (2009). Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72(18):1588-1594. — PubMed PMID: 19414726
20. Gaul C, Diener HC, Danesch U (2015). Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. Journal of Headache and Pain 16:516. — PubMed PMID: 25916335
21. Zempleni J, Galloway JR, McCormick DB (1996). Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. American Journal of Clinical Nutrition 63(1):54-66. — PubMed PMID: 8604671
22. Welch KM, Levine SR, D'Andrea G, Schultz LR, Helpern JA (1989). Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 39(4):538-541. — PubMed PMID: 2927679
23. Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpern JA, Welch KM (1989). Low brain magnesium in migraine. Headache 29(7):416-419. — PubMed PMID: 2759849

PubMed Topic Searches

1. PubMed: riboflavin migraine prophylaxis
2. PubMed: riboflavin + CoQ10 + magnesium migraine stack
3. PubMed: mitochondrial dysfunction migraine CSD
4. PubMed: pediatric migraine riboflavin
5. PubMed: AAN/AHS migraine complementary treatments guideline

Back to Table of Contents

Connections

• All Vitamins
• Vitamin B2 Overview
• B2 Benefits Hub
• B2 Mitochondrial Cofactor
• B2 Glutathione Reductase Cofactor
• B2 for MTHFR & Methylation
• Riboflavin and Migraine Prevention (Overview)
• Migraine (Disease)
• Migraine (Pain & Allergy)
• Magnesium Riboflavin and Supplements
• Migraine in Pregnancy and Breastfeeding
• CoQ10 for Migraine
• Magnesium
• Alpha Lipoic Acid for Mitochondria
• CoQ10
• Mitochondrial Dysfunction in CFS/ME
• Vitamin B6
• Deficiency
• Toxicity
• History
• Sources

Back to Table of Contents

Featured Videos